secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-145634
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Q1 net loss $42.1M; bemnifosbuvir misses primary endpoint but shows 71% hospitalization reduction
--------------------------------------------------------------------------------

- Net loss of $42.1M ($0.51 per diluted share) vs net income of $30.7M in Q1 2021; revenue $0 vs $65.985M due to Roche termination.
- Cash and equivalents $705.5M at March 31, 2022, down from $764.4M at Dec 31, 2021; $25M paid to Merck for ruzasvir license.
- Bemnifosbuvir MORNINGSKY trial: primary endpoint (time to symptom alleviation) not met; 71% reduction in hospitalization (2.9% vs 10%, p=0.047, exploratory).
- Phase 2 hospitalized COVID-19 study: 7.5% PRI on bemnifosbuvir vs 10% placebo; 0 deaths vs 3 deaths in placebo.
- Initiated Phase 2 DEFEND-2 and human challenge trial for AT-752 in dengue; results expected 4Q22 and late 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522145634/0001193125-22-145634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522145634/d259165d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-145634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer